glp 1 zepbound tirzepatide Zepbound: The newest obesity medication explained by an expert Use of the dual GIP/GLP-1
Description
2024;20 6 Suppl:S989
The answer is generally yes, as long as you maintain approximately weekly spacing going forward
Updated March 2025
Injection site reactions to tirzepatide present with characteristic local symptoms that patients should recognize
